Syndax Pharmaceuticals
SNDX
163 hedge funds and large institutions have $1.54B invested in Syndax Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 74 increasing their positions, 33 reducing their positions, and 26 closing their positions.
124% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 33
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
2% more funds holding
Funds holding: 160 → 163 (+3)
0.18% more ownership
Funds ownership: 106.47% → 106.65% (+0.18%)
14% less capital invested
Capital invested by funds: $1.78B → $1.54B (-$243M)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
44% less call options, than puts
Call options by funds: $1.97M | Put options by funds: $3.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$23.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$17.2M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$16M |
| 4 |
EP
Eversept Partners
New York
|
+$14.6M |
| 5 |
BlackRock
New York
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$49.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.4M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$12.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.93M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$9.42M |
SNDX Hedge Fund Activity: Q1 2023 in Review
163 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2023, worth a combined $1.54B — down 14% from $1.78B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SNDX positions and 26 closed out — a net gain of 5 holders — while 74 added to existing stakes and 33 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $23.5M. The largest seller was Avidity Partners Management, cutting an estimated $49.6M.
- 163 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2023, up from 160 in Q4 2022.
- Funds reported $1.54B of Syndax Pharmaceuticals stock for Q1 2023, down 14% quarter-over-quarter.
- 31 funds opened new Syndax Pharmaceuticals positions in Q1 2023 and 26 closed out, a net change of +5 holders.
- The largest Syndax Pharmaceuticals buyer in Q1 2023 was Morgan Stanley, an estimated $23.5M added.
- The largest Syndax Pharmaceuticals seller in Q1 2023 was Avidity Partners Management, an estimated $49.6M sold.
Based on aggregated 13F filings for Q1 2023.